Analysts Set AdaptHealth Corp. (NASDAQ:AHCO) PT at $11.67

AdaptHealth Corp. (NASDAQ:AHCO) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $11.67.

Several brokerages recently commented on AHCO. UBS Group decreased their target price on shares of AdaptHealth from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Canaccord Genuity Group decreased their price objective on shares of AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Royal Bank of Canada dropped their target price on shares of AdaptHealth from $13.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, November 19th. Truist Financial reduced their price target on AdaptHealth from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Finally, Robert W. Baird dropped their price objective on AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AHCO. JPMorgan Chase & Co. grew its stake in AdaptHealth by 73.2% in the third quarter. JPMorgan Chase & Co. now owns 191,833 shares of the company’s stock worth $2,154,000 after purchasing an additional 81,097 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of AdaptHealth by 39.7% during the 3rd quarter. Principal Financial Group Inc. now owns 543,744 shares of the company’s stock valued at $6,106,000 after buying an additional 154,434 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of AdaptHealth by 20.2% during the 3rd quarter. Franklin Resources Inc. now owns 65,601 shares of the company’s stock valued at $737,000 after buying an additional 11,037 shares in the last quarter. Geode Capital Management LLC grew its position in shares of AdaptHealth by 12.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,451,173 shares of the company’s stock worth $27,532,000 after buying an additional 265,712 shares during the period. Finally, Barclays PLC increased its stake in shares of AdaptHealth by 361.3% in the 3rd quarter. Barclays PLC now owns 181,240 shares of the company’s stock worth $2,034,000 after acquiring an additional 141,949 shares in the last quarter. Institutional investors own 82.67% of the company’s stock.

AdaptHealth Trading Down 2.7 %

Shares of AHCO opened at $9.53 on Thursday. AdaptHealth has a fifty-two week low of $6.46 and a fifty-two week high of $11.90. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -5.78, a PEG ratio of 1.36 and a beta of 1.10. The firm has a 50 day moving average price of $10.04 and a 200-day moving average price of $10.42. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.00 and a current ratio of 1.24.

AdaptHealth (NASDAQ:AHCO) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.02). AdaptHealth had a positive return on equity of 9.62% and a negative net margin of 6.57%. The business had revenue of $805.90 million during the quarter, compared to the consensus estimate of $809.32 million. During the same period in the prior year, the firm earned $0.19 earnings per share. The business’s revenue for the quarter was up .2% on a year-over-year basis. As a group, equities research analysts forecast that AdaptHealth will post 0.88 earnings per share for the current year.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.